Cyberknife treatment for advanced or terminal stage hepatocellular carcinoma

doi:10.3748/wjg.v21.i46.13101

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 46

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9318)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-6) series.

Item

Count

PDF

673

WORD

472

HTML

4704

Figures (1-2)

306

Tables (1-6)

484

Sum=6639

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1102

Download

1577

Sum=2679

Dec 14, 2015 (publication date) through Dec 11, 2024

Times Cited of This Article

Times Cited (13)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Dec 14, 2015; 21(46): 13101-13112
Published online Dec 14, 2015. doi: 10.3748/wjg.v21.i46.13101

Table 1 Patient characteristics n (%)

Characteristics	Parameter	Patients
No. of patients		65 (100)
Sex
	Male	51 (78)
	Female	14 (22)
Age, yr
	Median	71
	Minimum-Maximum	26-93
Viral hepatitis
	HCV	35 (54)
	HBV	9 (14)
	None	21 (32)
Child-Pugh classification
	A	38 (58)
	B	24 (37)
	C	2 (3)
	NA	1 (2)
ECOG perfomance status
	0	16 (25)
	1-2	43 (66)
	3	6 (9)
Previous treatments
	Surgery	24 (37)
	RFA	28 (43)
	TACE	49 (75)
	Sorafenib	13 (20)
	Radiation	7 (11)
BCLC stage
	C	59 (91)
	D	6 (9)
AFP (ng/mL)
	Median	256
	Minimum-Maximum	1-240700
PIVKA II (mAU/mL)
	Median	1431
	Minimum-Maximum	8-316400

ECOG: Eastern Cooperative Oncology Group; BCLC: Barcelona Clinic Liver Cancer staging system; AFP: Alpha fetoprotein; PIVKA II: Proteins induced by vitamin K absence; HCV: Hepatitis C virus; HBV: Hepatitis B virus; RFA: Radiofrequency ablation; TACE: Transarterial chemoembolization; NA: Not available.

Citation: Kato H, Yoshida H, Taniguch H, Nomura R, Sato K, Suzuki I, Nakata R. Cyberknife treatment for advanced or terminal stage hepatocellular carcinoma. World J Gastroenterol 2015; 21(46): 13101-13112
URL: https://www.wjgnet.com/1007-9327/full/v21/i46/13101.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i46.13101